Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: A randomized, double-blind, placebo-controlled study

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 6, 1998, Pages 682-685

  Elis, Avishay ^b   Bental, Tamir ^b   Kimchi, Oded ^b   Ravid, Mordchai ^b   Lishner, Michael ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; PLACEBO;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; FEMALE; HEMODYNAMICS; HUMAN; HYPERTENSION; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SURVIVAL RATE;

ADRENERGIC BETA-AGONISTS; AGED; CARDIOTONIC AGENTS; CHRONIC DISEASE; DOBUTAMINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MYOCARDIAL ISCHEMIA; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031846408     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90092-3     Document Type: Article

References (21)

1. Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975;36:185-96.
2. Beanlands RB, Bach DS, Raylman R, Armstrong WF, Wilson V, Montieth M, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-II acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol 1993;22:1389-98.
3. Erlemier HH, Kupper W, Bllifeld W. Effect of dobutamine on pulmonary gas exchange in patients with severe heart failure. Eur Heart J 1992;13:1545-8.
4. Gibelin P, Sbirrazzuvoli V, Drici M, Camous JP, Lapalus P, Morand P. Effects of short-term administration of dobutamine on left ventricular performance, exercise capacity, norepinephrine levels and lymphocyte adrenergic receptor density in congestive heart failure. Cardiovasc Drugs Ther 1990;4:1105-11.
5. Unverferth DV, Magorien RD, Lewis PR, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980;100:622-30.
6. Liang CS, Sheman LG, Doherty JU, Wellington K, Lee VW, Hood WB Jr. Sustained improvement in patients with congestive heart failure after short-term infusion of dobutamine. Circulation 1984;69:113-9.
7. Leier CV, Huss P, Lewis RP, Unverferth DV. Drug induced conditioning in congestive heart failure. Circulation 1984;65:1382-7.
8. Dies F, Krell MJ, Whitlow P, Liang C, Goldenberg I, Applefeld MM, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure [abstract]. Circulation 1986;74(suppl II):38.
9. Hilleman DE, Mohiuddin SM. Changing strategies in the management of chronic congestive heart failure. Drug Intell Clin Pharm 1991;25:1349-54.
10. Om A, Hess ML. Inotropic therapy of the failing myocardium. Clin Cardiol 1993;16:5-14.
11. Massie BM, Shah NB. Future approaches to pharmacologic therapy for congestive heart failure. Curr Opin Cardiol 1995;10:229-37.
12. Armstrong PW, Moe GW. Medical advances in the treatment of congestive heart failure. Circulation 1994;88: 2941-52.
13. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Dibianco R, Zeldis SM, et al, for the Promise Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
14. Rich MW, Woods WL, Davila-Roman VG, Morello PJ, Kurz H, Barbarash R, et al. A randomized comparison of intravenous amrinone versus dobutamine in older patients with decompensated congestive heart failure. J Am Geriatr Soc 1995;43:271-4.
15. Thuillez C, Richard C, Teboul JL, Annane D, Bellissant E, Auzepy P, et al. Arterial hemodynamics and cardiac effects of enoximone, dobutmaine and their combination in severe heart failure. Am Heart J 1993;125:799-808.
16. Gibelin P, Bossan P, Ferrari E, Drici M, Morand P. Treatment of chronic heart insufficiency with dobutamine. Interet et limites. Press Med 1992;21:1680-4.
17. Pickworth KK. Long-term dobutamine therapy for refractory congestive heart failure. Clin Pharmacokinet 1992;11:618-24.
18. Marcon JL, Bonijoly S, Farre E. Intermittent infusions of dobutamine in the treatment of chronic cardiac failure in the terminal stage. Ann Cardiol Angliol 1993;42: 495-502.
19. Frey B, Wutte M, Berger R, Ioannides C, Hulsmann M, Stanek B, et al. Sudden death and staged therapy for hemodynamic stabilization in patients enrolled in a heart transplantation program. Pacing Clin Electrophysiol 1995;18:152-8.
20. Erlemeier HH, Kupper W, Bleifeld W. Intermittent infusion of dobutamine in the therapy of severe congestive heart failure: long-term effects and lack of tolerance. Cardiovasc Drugs Ther 1992;6:391-8.
21. Vanden Brande P, Van Mieghem W, Demedts M. Intermittent dobutamine infusion in severe chronic heart failure in elderly patients. Gerontology 1990;36:49-54.